Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,786
archived clinical trials in
Dermatology

A Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis (SSc)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Tocilizumab Versus Placebo in Patients With Systemic Sclerosis
Status: Enrolling
Updated:  12/31/1969
University of Texas Rheumatology Clinic
1357
mi
from 91732
Houston, TX
A Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis (SSc)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Tocilizumab Versus Placebo in Patients With Systemic Sclerosis
Status: Enrolling
Updated: 12/31/1969
University of Texas Rheumatology Clinic
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis (SSc)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Tocilizumab Versus Placebo in Patients With Systemic Sclerosis
Status: Enrolling
Updated:  12/31/1969
Swedish Research Center
961
mi
from 91732
Seattle, WA
A Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis (SSc)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Tocilizumab Versus Placebo in Patients With Systemic Sclerosis
Status: Enrolling
Updated: 12/31/1969
Swedish Research Center
961
mi
from 91732
Seattle, WA
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis (SSc)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Tocilizumab Versus Placebo in Patients With Systemic Sclerosis
Status: Enrolling
Updated:  12/31/1969
Organizacion Medica de Investigacion
6112
mi
from 91732
Buenos Aires,
A Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis (SSc)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Tocilizumab Versus Placebo in Patients With Systemic Sclerosis
Status: Enrolling
Updated: 12/31/1969
Organizacion Medica de Investigacion
6112
mi
from 91732
Buenos Aires,
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis (SSc)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Tocilizumab Versus Placebo in Patients With Systemic Sclerosis
Status: Enrolling
Updated:  12/31/1969
St. Joseph's Heritage Healthcare
13
mi
from 91732
Fullerton, CA
A Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis (SSc)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Tocilizumab Versus Placebo in Patients With Systemic Sclerosis
Status: Enrolling
Updated: 12/31/1969
St. Joseph's Heritage Healthcare
13
mi
from 91732
Fullerton, CA
Click here to add this to my saved trials
Topical NVN1000 for the Treatment of External Genital and Perianal Warts
A Phase 2, Multi-center, Double-blind, Randomized, Vehicle-controlled, Ascending Dose Study Assessing Tolerability, Safety, and Efficacy of Topical NVN1000 in Subjects With External Genital Warts and Perianal Warts
Status: Enrolling
Updated:  12/31/1969
PPD 133
100
mi
from 91732
San Diego, CA
Topical NVN1000 for the Treatment of External Genital and Perianal Warts
A Phase 2, Multi-center, Double-blind, Randomized, Vehicle-controlled, Ascending Dose Study Assessing Tolerability, Safety, and Efficacy of Topical NVN1000 in Subjects With External Genital Warts and Perianal Warts
Status: Enrolling
Updated: 12/31/1969
PPD 133
100
mi
from 91732
San Diego, CA
Click here to add this to my saved trials
Topical NVN1000 for the Treatment of External Genital and Perianal Warts
A Phase 2, Multi-center, Double-blind, Randomized, Vehicle-controlled, Ascending Dose Study Assessing Tolerability, Safety, and Efficacy of Topical NVN1000 in Subjects With External Genital Warts and Perianal Warts
Status: Enrolling
Updated:  12/31/1969
PPD 134
1924
mi
from 91732
Atlanta, GA
Topical NVN1000 for the Treatment of External Genital and Perianal Warts
A Phase 2, Multi-center, Double-blind, Randomized, Vehicle-controlled, Ascending Dose Study Assessing Tolerability, Safety, and Efficacy of Topical NVN1000 in Subjects With External Genital Warts and Perianal Warts
Status: Enrolling
Updated: 12/31/1969
PPD 134
1924
mi
from 91732
Atlanta, GA
Click here to add this to my saved trials
Topical NVN1000 for the Treatment of External Genital and Perianal Warts
A Phase 2, Multi-center, Double-blind, Randomized, Vehicle-controlled, Ascending Dose Study Assessing Tolerability, Safety, and Efficacy of Topical NVN1000 in Subjects With External Genital Warts and Perianal Warts
Status: Enrolling
Updated:  12/31/1969
PPD 130
1792
mi
from 91732
Indianapolis, IN
Topical NVN1000 for the Treatment of External Genital and Perianal Warts
A Phase 2, Multi-center, Double-blind, Randomized, Vehicle-controlled, Ascending Dose Study Assessing Tolerability, Safety, and Efficacy of Topical NVN1000 in Subjects With External Genital Warts and Perianal Warts
Status: Enrolling
Updated: 12/31/1969
PPD 130
1792
mi
from 91732
Indianapolis, IN
Click here to add this to my saved trials
Topical NVN1000 for the Treatment of External Genital and Perianal Warts
A Phase 2, Multi-center, Double-blind, Randomized, Vehicle-controlled, Ascending Dose Study Assessing Tolerability, Safety, and Efficacy of Topical NVN1000 in Subjects With External Genital Warts and Perianal Warts
Status: Enrolling
Updated:  12/31/1969
PPD 126
1647
mi
from 91732
Metairie, LA
Topical NVN1000 for the Treatment of External Genital and Perianal Warts
A Phase 2, Multi-center, Double-blind, Randomized, Vehicle-controlled, Ascending Dose Study Assessing Tolerability, Safety, and Efficacy of Topical NVN1000 in Subjects With External Genital Warts and Perianal Warts
Status: Enrolling
Updated: 12/31/1969
PPD 126
1647
mi
from 91732
Metairie, LA
Click here to add this to my saved trials
Topical NVN1000 for the Treatment of External Genital and Perianal Warts
A Phase 2, Multi-center, Double-blind, Randomized, Vehicle-controlled, Ascending Dose Study Assessing Tolerability, Safety, and Efficacy of Topical NVN1000 in Subjects With External Genital Warts and Perianal Warts
Status: Enrolling
Updated:  12/31/1969
PPD 132
828
mi
from 91732
Portland, OR
Topical NVN1000 for the Treatment of External Genital and Perianal Warts
A Phase 2, Multi-center, Double-blind, Randomized, Vehicle-controlled, Ascending Dose Study Assessing Tolerability, Safety, and Efficacy of Topical NVN1000 in Subjects With External Genital Warts and Perianal Warts
Status: Enrolling
Updated: 12/31/1969
PPD 132
828
mi
from 91732
Portland, OR
Click here to add this to my saved trials
Topical NVN1000 for the Treatment of External Genital and Perianal Warts
A Phase 2, Multi-center, Double-blind, Randomized, Vehicle-controlled, Ascending Dose Study Assessing Tolerability, Safety, and Efficacy of Topical NVN1000 in Subjects With External Genital Warts and Perianal Warts
Status: Enrolling
Updated:  12/31/1969
PPD 135
2375
mi
from 91732
Philadelphia, PA
Topical NVN1000 for the Treatment of External Genital and Perianal Warts
A Phase 2, Multi-center, Double-blind, Randomized, Vehicle-controlled, Ascending Dose Study Assessing Tolerability, Safety, and Efficacy of Topical NVN1000 in Subjects With External Genital Warts and Perianal Warts
Status: Enrolling
Updated: 12/31/1969
PPD 135
2375
mi
from 91732
Philadelphia, PA
Click here to add this to my saved trials
Topical NVN1000 for the Treatment of External Genital and Perianal Warts
A Phase 2, Multi-center, Double-blind, Randomized, Vehicle-controlled, Ascending Dose Study Assessing Tolerability, Safety, and Efficacy of Topical NVN1000 in Subjects With External Genital Warts and Perianal Warts
Status: Enrolling
Updated:  12/31/1969
PPD 128
1293
mi
from 91732
Corpus Christi, TX
Topical NVN1000 for the Treatment of External Genital and Perianal Warts
A Phase 2, Multi-center, Double-blind, Randomized, Vehicle-controlled, Ascending Dose Study Assessing Tolerability, Safety, and Efficacy of Topical NVN1000 in Subjects With External Genital Warts and Perianal Warts
Status: Enrolling
Updated: 12/31/1969
PPD 128
1293
mi
from 91732
Corpus Christi, TX
Click here to add this to my saved trials
Topical NVN1000 for the Treatment of External Genital and Perianal Warts
A Phase 2, Multi-center, Double-blind, Randomized, Vehicle-controlled, Ascending Dose Study Assessing Tolerability, Safety, and Efficacy of Topical NVN1000 in Subjects With External Genital Warts and Perianal Warts
Status: Enrolling
Updated:  12/31/1969
PPD 129
1358
mi
from 91732
Houston, TX
Topical NVN1000 for the Treatment of External Genital and Perianal Warts
A Phase 2, Multi-center, Double-blind, Randomized, Vehicle-controlled, Ascending Dose Study Assessing Tolerability, Safety, and Efficacy of Topical NVN1000 in Subjects With External Genital Warts and Perianal Warts
Status: Enrolling
Updated: 12/31/1969
PPD 129
1358
mi
from 91732
Houston, TX
Click here to add this to my saved trials
Topical NVN1000 for the Treatment of External Genital and Perianal Warts
A Phase 2, Multi-center, Double-blind, Randomized, Vehicle-controlled, Ascending Dose Study Assessing Tolerability, Safety, and Efficacy of Topical NVN1000 in Subjects With External Genital Warts and Perianal Warts
Status: Enrolling
Updated:  12/31/1969
PPD 127
1188
mi
from 91732
San Antonio, TX
Topical NVN1000 for the Treatment of External Genital and Perianal Warts
A Phase 2, Multi-center, Double-blind, Randomized, Vehicle-controlled, Ascending Dose Study Assessing Tolerability, Safety, and Efficacy of Topical NVN1000 in Subjects With External Genital Warts and Perianal Warts
Status: Enrolling
Updated: 12/31/1969
PPD 127
1188
mi
from 91732
San Antonio, TX
Click here to add this to my saved trials
Topical NVN1000 for the Treatment of External Genital and Perianal Warts
A Phase 2, Multi-center, Double-blind, Randomized, Vehicle-controlled, Ascending Dose Study Assessing Tolerability, Safety, and Efficacy of Topical NVN1000 in Subjects With External Genital Warts and Perianal Warts
Status: Enrolling
Updated:  12/31/1969
PPD 131
1377
mi
from 91732
Webster, TX
Topical NVN1000 for the Treatment of External Genital and Perianal Warts
A Phase 2, Multi-center, Double-blind, Randomized, Vehicle-controlled, Ascending Dose Study Assessing Tolerability, Safety, and Efficacy of Topical NVN1000 in Subjects With External Genital Warts and Perianal Warts
Status: Enrolling
Updated: 12/31/1969
PPD 131
1377
mi
from 91732
Webster, TX
Click here to add this to my saved trials
Topical NVN1000 for the Treatment of External Genital and Perianal Warts
A Phase 2, Multi-center, Double-blind, Randomized, Vehicle-controlled, Ascending Dose Study Assessing Tolerability, Safety, and Efficacy of Topical NVN1000 in Subjects With External Genital Warts and Perianal Warts
Status: Enrolling
Updated:  12/31/1969
PPD 137
25
mi
from 91732
Fountain Valley, CA
Topical NVN1000 for the Treatment of External Genital and Perianal Warts
A Phase 2, Multi-center, Double-blind, Randomized, Vehicle-controlled, Ascending Dose Study Assessing Tolerability, Safety, and Efficacy of Topical NVN1000 in Subjects With External Genital Warts and Perianal Warts
Status: Enrolling
Updated: 12/31/1969
PPD 137
25
mi
from 91732
Fountain Valley, CA
Click here to add this to my saved trials
Topical NVN1000 for the Treatment of External Genital and Perianal Warts
A Phase 2, Multi-center, Double-blind, Randomized, Vehicle-controlled, Ascending Dose Study Assessing Tolerability, Safety, and Efficacy of Topical NVN1000 in Subjects With External Genital Warts and Perianal Warts
Status: Enrolling
Updated:  12/31/1969
PPD 140
25
mi
from 91732
Lomita, CA
Topical NVN1000 for the Treatment of External Genital and Perianal Warts
A Phase 2, Multi-center, Double-blind, Randomized, Vehicle-controlled, Ascending Dose Study Assessing Tolerability, Safety, and Efficacy of Topical NVN1000 in Subjects With External Genital Warts and Perianal Warts
Status: Enrolling
Updated: 12/31/1969
PPD 140
25
mi
from 91732
Lomita, CA
Click here to add this to my saved trials
Topical NVN1000 for the Treatment of External Genital and Perianal Warts
A Phase 2, Multi-center, Double-blind, Randomized, Vehicle-controlled, Ascending Dose Study Assessing Tolerability, Safety, and Efficacy of Topical NVN1000 in Subjects With External Genital Warts and Perianal Warts
Status: Enrolling
Updated:  12/31/1969
PPD 139
1919
mi
from 91732
Atlanta, GA
Topical NVN1000 for the Treatment of External Genital and Perianal Warts
A Phase 2, Multi-center, Double-blind, Randomized, Vehicle-controlled, Ascending Dose Study Assessing Tolerability, Safety, and Efficacy of Topical NVN1000 in Subjects With External Genital Warts and Perianal Warts
Status: Enrolling
Updated: 12/31/1969
PPD 139
1919
mi
from 91732
Atlanta, GA
Click here to add this to my saved trials
Topical NVN1000 for the Treatment of External Genital and Perianal Warts
A Phase 2, Multi-center, Double-blind, Randomized, Vehicle-controlled, Ascending Dose Study Assessing Tolerability, Safety, and Efficacy of Topical NVN1000 in Subjects With External Genital Warts and Perianal Warts
Status: Enrolling
Updated:  12/31/1969
PPD 136
961
mi
from 91732
Seattle, WA
Topical NVN1000 for the Treatment of External Genital and Perianal Warts
A Phase 2, Multi-center, Double-blind, Randomized, Vehicle-controlled, Ascending Dose Study Assessing Tolerability, Safety, and Efficacy of Topical NVN1000 in Subjects With External Genital Warts and Perianal Warts
Status: Enrolling
Updated: 12/31/1969
PPD 136
961
mi
from 91732
Seattle, WA
Click here to add this to my saved trials
Topical NVN1000 for the Treatment of External Genital and Perianal Warts
A Phase 2, Multi-center, Double-blind, Randomized, Vehicle-controlled, Ascending Dose Study Assessing Tolerability, Safety, and Efficacy of Topical NVN1000 in Subjects With External Genital Warts and Perianal Warts
Status: Enrolling
Updated:  12/31/1969
PPD 138
1914
mi
from 91732
Roswell, GA
Topical NVN1000 for the Treatment of External Genital and Perianal Warts
A Phase 2, Multi-center, Double-blind, Randomized, Vehicle-controlled, Ascending Dose Study Assessing Tolerability, Safety, and Efficacy of Topical NVN1000 in Subjects With External Genital Warts and Perianal Warts
Status: Enrolling
Updated: 12/31/1969
PPD 138
1914
mi
from 91732
Roswell, GA
Click here to add this to my saved trials
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)
Status: Enrolling
Updated:  12/31/1969
Novartis Investigator Site
1785
mi
from 91732
Birmingham, AL
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)
Status: Enrolling
Updated: 12/31/1969
Novartis Investigator Site
1785
mi
from 91732
Birmingham, AL
Click here to add this to my saved trials
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
352
mi
from 91732
Scottsdale, AZ
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
352
mi
from 91732
Scottsdale, AZ
Click here to add this to my saved trials
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1458
mi
from 91732
Little Rock, AR
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1458
mi
from 91732
Little Rock, AR
Click here to add this to my saved trials
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
24
mi
from 91732
Huntington Beach, CA
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
24
mi
from 91732
Huntington Beach, CA
Click here to add this to my saved trials
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
37
mi
from 91732
Mission Viejo, CA
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
37
mi
from 91732
Mission Viejo, CA
Click here to add this to my saved trials
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)
Status: Enrolling
Updated:  12/31/1969
Novartis Investigator Site
1715
mi
from 91732
Evansville, IN
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)
Status: Enrolling
Updated: 12/31/1969
Novartis Investigator Site
1715
mi
from 91732
Evansville, IN
Click here to add this to my saved trials
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1812
mi
from 91732
Louisville, KY
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1812
mi
from 91732
Louisville, KY
Click here to add this to my saved trials
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)
Status: Enrolling
Updated:  12/31/1969
Novartis Investigator Site
1736
mi
from 91732
Owensboro, KY
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)
Status: Enrolling
Updated: 12/31/1969
Novartis Investigator Site
1736
mi
from 91732
Owensboro, KY
Click here to add this to my saved trials
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
2289
mi
from 91732
Waldorf, MD
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
2289
mi
from 91732
Waldorf, MD
Click here to add this to my saved trials
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)
Status: Enrolling
Updated:  12/31/1969
Novartis Investigator Site
1509
mi
from 91732
Minneapolis, MN
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)
Status: Enrolling
Updated: 12/31/1969
Novartis Investigator Site
1509
mi
from 91732
Minneapolis, MN
Click here to add this to my saved trials
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1524
mi
from 91732
Rochester, MN
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1524
mi
from 91732
Rochester, MN
Click here to add this to my saved trials
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
2440
mi
from 91732
Forest Hills, NY
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
2440
mi
from 91732
Forest Hills, NY
Click here to add this to my saved trials
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
2003
mi
from 91732
Asheville, NC
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
2003
mi
from 91732
Asheville, NC
Click here to add this to my saved trials
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1881
mi
from 91732
Cincinnati, OH
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1881
mi
from 91732
Cincinnati, OH
Click here to add this to my saved trials
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1933
mi
from 91732
Toledo, OH
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1933
mi
from 91732
Toledo, OH
Click here to add this to my saved trials
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)
Status: Enrolling
Updated:  12/31/1969
Novartis Investigational Site
821
mi
from 91732
Lake Oswego, OR
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)
Status: Enrolling
Updated: 12/31/1969
Novartis Investigational Site
821
mi
from 91732
Lake Oswego, OR
Click here to add this to my saved trials
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative site
2562
mi
from 91732
Providence, RI
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative site
2562
mi
from 91732
Providence, RI
Click here to add this to my saved trials
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative site
1225
mi
from 91732
Dallas, TX
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative site
1225
mi
from 91732
Dallas, TX
Click here to add this to my saved trials
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1195
mi
from 91732
Fort Worth, TX
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1195
mi
from 91732
Fort Worth, TX
Click here to add this to my saved trials
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1337
mi
from 91732
Katy, TX
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1337
mi
from 91732
Katy, TX
Click here to add this to my saved trials
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
2469
mi
from 91732
South Burlington, VT
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
2469
mi
from 91732
South Burlington, VT
Click here to add this to my saved trials
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
939
mi
from 91732
Spokane, WA
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
939
mi
from 91732
Spokane, WA
Click here to add this to my saved trials
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
2148
mi
from 91732
Sarasota, FL
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
2148
mi
from 91732
Sarasota, FL
Click here to add this to my saved trials
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from 91732
Campbelltown,
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from 91732
Campbelltown,
Click here to add this to my saved trials
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1562
mi
from 91732
Saint Louis, MO
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1562
mi
from 91732
Saint Louis, MO
Click here to add this to my saved trials
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
2441
mi
from 91732
Bronx, NY
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
2441
mi
from 91732
Bronx, NY
Click here to add this to my saved trials
Efficacy and Tolerability of Topical LFX453 for External Genital Warts
A Randomized, Vehicle Controlled, Active Comparator, Parallel Group Study to Evaluate Efficacy, Safety, and Tolerability of Topical LFX453 Formulations in Patients With External Genital Warts (EGWs)
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1713
mi
from 91732
Arlington Heights, IL
Efficacy and Tolerability of Topical LFX453 for External Genital Warts
A Randomized, Vehicle Controlled, Active Comparator, Parallel Group Study to Evaluate Efficacy, Safety, and Tolerability of Topical LFX453 Formulations in Patients With External Genital Warts (EGWs)
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1713
mi
from 91732
Arlington Heights, IL
Click here to add this to my saved trials
A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing
A Phase 2, Multicenter, Randomized, Double-Blind Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia (AGA) Analyzed by Biopsy of the Scalp Prior To and Post Dosing
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1973
mi
from 91732
Clinton Township, MI
A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing
A Phase 2, Multicenter, Randomized, Double-Blind Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia (AGA) Analyzed by Biopsy of the Scalp Prior To and Post Dosing
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1973
mi
from 91732
Clinton Township, MI
Click here to add this to my saved trials
A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing
A Phase 2, Multicenter, Randomized, Double-Blind Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia (AGA) Analyzed by Biopsy of the Scalp Prior To and Post Dosing
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2032
mi
from 91732
Cleveland, OH
A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing
A Phase 2, Multicenter, Randomized, Double-Blind Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia (AGA) Analyzed by Biopsy of the Scalp Prior To and Post Dosing
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2032
mi
from 91732
Cleveland, OH
Click here to add this to my saved trials
A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing
A Phase 2, Multicenter, Randomized, Double-Blind Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia (AGA) Analyzed by Biopsy of the Scalp Prior To and Post Dosing
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1284
mi
from 91732
College Station, TX
A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing
A Phase 2, Multicenter, Randomized, Double-Blind Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia (AGA) Analyzed by Biopsy of the Scalp Prior To and Post Dosing
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1284
mi
from 91732
College Station, TX
Click here to add this to my saved trials
A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing
A Phase 2, Multicenter, Randomized, Double-Blind Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia (AGA) Analyzed by Biopsy of the Scalp Prior To and Post Dosing
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1357
mi
from 91732
Houston, TX
A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing
A Phase 2, Multicenter, Randomized, Double-Blind Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia (AGA) Analyzed by Biopsy of the Scalp Prior To and Post Dosing
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials